{{Rsnum
|rsid=997669
|Gene=CCNE1
|Chromosome=19
|position=29813576
|Orientation=minus
|GMAF=0.2218
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
|Gene_s=CCNE1
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 38.9 | 49.6 | 11.5
| HCB | 81.0 | 19.0 | 0.0
| JPT | 85.0 | 14.2 | 0.9
| YRI | 82.3 | 15.6 | 2.0
| ASW | 84.2 | 14.0 | 1.8
| CHB | 81.0 | 19.0 | 0.0
| CHD | 83.5 | 15.6 | 0.9
| GIH | 57.4 | 39.6 | 3.0
| LWK | 74.5 | 23.6 | 1.8
| MEX | 63.8 | 31.0 | 5.2
| MKK | 85.9 | 12.8 | 1.3
| TSI | 49.0 | 40.2 | 10.8
| HapMapRevision=28
}}[[rs997669]] shows an association with [[breast cancer]] in a British study involving ~2300 patients. The odds ratio for the (G;G) vs (A;A) homozygotes is 1.18 (CI: 1.04-1.34, p=0.003).{{PMID|18174243|OA=1
}}

{{PMID Auto
|PMID=19124506
|Title=Common genetic variation in candidate genes and susceptibility to subtypes of breast cancer.
|OA=1
}}

{{PMID Auto
|PMID=19258477
|Title=Candidate gene analysis using imputed genotypes: cell cycle single-nucleotide polymorphisms and ovarian cancer risk.
|OA=1
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}